Fostemsavir

Fostemsavir is a gp120 attachment inhibitor.

ARV U.S. Brand Name
Rukobia
ARV Abbreviation(s)
FTR
U.S. FDA Label
Rukobia Labeling (Package Insert)
ARV Class
Entry, fusion, and attachment inhibitors
First U.S. Approval
U.S. Manufacturer
ViiV Healthcare
Formulations
Strength Formulation Image Description Boosted
600 mg
Extended-release (XR) Tablet
beige oval tablet with SV 1V7 imprinted on one side
Beige oval tablet with SV 1V7 imprinted on one side
No
Generic Available?
No
Other Reference Links
National HIV Curriculum
U.S. Guidelines Links
Clinical Info Drug Database
Assistance Programs
ViiV Connect
Displaying 1 - 33 of 33
Interaction Color Code Clinical Bottom Line Clinical Effects Drug 1 effect Drug 2 dose Drug 2 effect Management
Fostemsavir Simvastatin 32 Orange: Minimal data to guide interaction Minimal data to guide interaction: weigh risks and benefits of using this combination

Increased statin exposure and risk of statin associated adverse events

If co-adminstering, use lowest possible starting dose and monitor for statin associated adverse events
Fostemsavir Pitavastatin 31 Orange: Minimal data to guide interaction Minimal data to guide interaction: weigh risks and benefits of using this combination

Increased statin exposure and risk of statin associated adverse events

If co-adminstering, use lowest possible starting dose and monitor for statin associated adverse events
Fostemsavir Fluvastatin 30 Orange: Minimal data to guide interaction Minimal data to guide interaction: weigh risks and benefits of using this combination

Increased statin exposure and risk of statin associated adverse events

If co-adminstering, use lowest possible starting dose and monitor for statin associated adverse events
Fostemsavir Atorvastatin 29 Orange: Minimal data to guide interaction Minimal data to guide interaction: weigh risks and benefits of using this combination

Increased statin exposure and risk of statin associated adverse events

If co-adminstering, use lowest possible starting dose and monitor for statin associated adverse events
Fostemsavir Doxorubicin 28 Orange: Minimal data to guide interaction Minimal data to guide interaction: risks likely to outweigh benefits benefit

Increased exposure of doxorubicin

If co-adminstering, monitor for adverse effects
Fostemsavir Elbasvir / grazoprevir 27 Orange: Minimal data to guide interaction Minimal data to guide interaction: risks likely to outweigh benefits benefit

Potentially increased exposure of grazoprevir and risk of ALT elevations

Avoid combination; use alternative HCV regimen
Fostemsavir SOF/VEL/VOX 26 Orange: Minimal data to guide interaction Minimal data to guide interaction: risks likely to outweigh benefits benefit

Increased exposure of voxilaprevir and risk of ALT elevations

Avoid combination; use alternative HCV regimen
Fostemsavir Ethinyl estradiol / Norethindrone acetate 25 Orange: Minimal data to guide interaction Minimal data to guide interaction, weigh risks and benefits of using this combination

Increased ethinyl estradiol exposure and increased risk of thromboembolic events

Not reported

 0.030 / 1.5mg once daily

EE: Cmax increased 39%, AUC increased 40%; NE: Cmax increased 8%, AUC increased 8%

If co-adminstering, ethinyl estradiol daily dose should not exceed 30 mcg. Further caution advised if patient is at increased risk for thromboembolic events.
Fostemsavir RIF 24 Red: Avoid combination Do not coadminister: Reduced levels of temsavir

Potential decrease in antiretroviral efficacy

Temsavir Cmax decreased 76%, AUC decreased 82%

 600 mg once daily

Not reported

Contraindicated. Use alternative agents.
Fostemsavir RPT 23 Red: Avoid combination Do not coadminister: Potential for reduced levels of temsavir

Potential decrease in antiretroviral efficacy

Contraindicated. Use alternative agents.
Fostemsavir St. John's Wort (Hypericum perforatum) 22 Red: Avoid combination Do not coadminister: Potential for reduced levels of temsavir

Potential decrease in antiretroviral efficacy

Contraindicated. Use alternative agents.
Fostemsavir Phenytoin 21 Red: Avoid combination Do not coadminister: Potential for reduced levels of temsavir

Potential decrease in antiretroviral efficacy

Contraindicated. Use alternative agents.
Fostemsavir Phenobarbital 20 Red: Avoid combination Do not coadminister: Potential for reduced levels of temsavir

Potential decrease in antiretroviral efficacy

Contraindicated. Use alternative agents.
Fostemsavir Mitotane 19 Red: Avoid combination Do not coadminister: Potential for reduced levels of temsavir

Potential decrease in antiretroviral efficacy

Contraindicated. Use alternative agents.
Fostemsavir Enzalutamide 18 Red: Avoid combination Do not coadminister: Potential for reduced levels of temsavir

Potential decrease in antiretroviral efficacy

Contraindicated. Use alternative agents.
Fostemsavir CBZ 17 Red: Avoid combination Do not coadminister: Potential for reduced levels of temsavir

Potential decrease in antiretroviral efficacy

Contraindicated. Use alternative agents.
Fostemsavir RAL + TDF 16 Green: Administer standard doses Administer standard doses

Temsavir Cmax increased 23%, AUC increased 7%, Cmin increased 17%

 RAL 400 mg BID, TDF 300 mg once daily

Not reported
Fostemsavir Famotidine 15 Green: Administer standard doses Administer standard doses

Temsavir Cmax increased 1%, AUC increased 4%, Cmin decreased 10%

 40mg single dose

Not reported
Fostemsavir Methadone 14 Green: Administer standard doses Administer standard doses

Not studied

 40-120mg once daily, individual dosing

Methadone R(-): Cmax increased 15%, AUC increased 13%. Methadone S(+): Cmax increased 15%, AUC increased 15%, Cmin increased 10%. Methadone (total): Cmax increased 25%, AUC increased 14%, Cmin increased 10%
Fostemsavir MVC 13 Green: Administer standard doses Administer standard doses

Temsavir Cmax increased 13%, AUC increased 10%, Cmin decreased 10%

 300 mg BID

Maraviroc AUC increased 25%, Cmin increased 37%
Fostemsavir Buprenorphine / naloxone 12 Green: Administer standard doses Administer standard doses

Not studied

 8mg / 2mg to 24mg / 6mg once daily, individual dosing

Buprenorphine Cmax increased 24%, AUC increased 30%, Cmin increased 39%. Norbuprenorphine Cmax increased 24%, AUC increased 39%, Cmin increased 39%
Fostemsavir DRV/c 11 Green: Administer standard doses Administer standard doses

Temsavir Cmax increased 79%, AUC increased 97%, Cmin increased 124%

 800 / 150 mg once daily

Not studied
Fostemsavir Cobi 10 Green: Administer standard doses Administer standard doses

Temsavir Cmax increased 71%, AUC increased 93%, Cmin increased 136%

 150 mg once daily

Not studied
Fostemsavir RTV 9 Green: Administer standard doses Administer standard doses

Temsavir Cmax increased 53%, AUC increased 45%, Cmin increased 44%

 100 mg once daily

Not reported
Fostemsavir DRV/r + ETR 8 Green: Administer standard doses Administer standard doses

Temsavir Cmax increased 53%, AUC increased 34%, Cmin increased 33%

 DRV 600mg twice daily, / r 100mg twice daily, ETR 200mg twice daily

DRV and ritonavir no significant changes. Etravirine Cmax increased 18%, AUC increased 28%, Cmin increased 28%.
Fostemsavir DRV/r 7 Green: Administer standard doses Administer standard doses

Temsavir Cmax increased 52%, AUC increased 63%, Cmin increased 88%

 DRV 600mg twice daily, / r 100mg twice daily

DRV no significant change. Ritonavir AUC increased 15%, Cmin increased 19%
Fostemsavir ATV/r 6 Green: Administer standard doses Administer standard doses

Temsavir Cmax increased 68%, AUC increased 54%, Cmin increased 57%

 ATV 300mg, / r 100mg once daily

ATV: Cmax increased 3%, AUC increased 9%, Cmin increased 19%; / r: Cmax increased 2%, AUC increased 7%, Cmin increased 22%
Fostemsavir ETR 5 Green: Administer standard doses Administer standard doses

Temsavir Cmax decreased 48%, AUC decreased 50%, Cmin decreased 48%

 200 mg BID

Etravirine Cmax increased 11%, AUC increased 11%, Cmin increased 14%
Fostemsavir TDF 4 Green: Administer standard doses Administer standard doses

Temsavir Cmax decreased 1%, Cmin increased 13%

 300 mg once daily

Cmax increased 18%, AUC increased 19%, Cmin increased 28%
Fostemsavir Rosuvastatin 3 Yellow: Adjust dosing Adjust dosing to avoid increased levels of rosuvastatin

Increased statin exposure and risk of statin associated adverse events

Not studied

 10 mg single dose

Cmax increased 78%, AUC increased 69%

If co-adminstering, use lowest possible starting dose and monitor for statin associated adverse events
Fostemsavir RFB 2 Yellow: Adjust dosing Adjust dosing to avoid increased levels of rifabutin

Temsavir Cmax decreased 27%, AUC decreased 30%, Cmin decreased 41%

 300 mg once daily

Not reported

Use standard dose rifabutin if coadministering with fostemsavir. If using fostemsavir in combination with a ritonavir boosted protease inhibitor, lower rifabutin dose to 150 mg daily.
Fostemsavir RFB + RTV 1 Yellow: Adjust dosing Adjust dosing to avoid increased levels of rifabutin

Temsavir Cmax increased 50%, AUC increased 66%, Cmin increased 158%

 RFB 150 mg once daily, RTV 100 mg once daily

Not reported

Use standard dose rifabutin if coadministering with fostemsavir. If using fostemsavir in combination with a ritonavir boosted protease inhibitor, lower rifabutin dose to 150 mg daily.
Fostemsavir
Subscribe to Fostemsavir